[
    [
        {
            "time": "2020-01-01",
            "original_text": "疫苗行业喜报频传，业绩下降仅一家，最高涨幅达600% 盈利能力下降",
            "features": {
                "keywords": [
                    "疫苗行业",
                    "喜报频传",
                    "业绩下降",
                    "最高涨幅",
                    "盈利能力下降"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "疫苗行业喜报频传，业绩下降仅一家，最高涨幅达600% 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-01-01",
            "original_text": "生物制品-创新疫苗大产品大时代将进入第二波大浪潮，板块迎来布局良机【国盛医药张金洋团队】",
            "features": {
                "keywords": [
                    "生物制品",
                    "创新疫苗",
                    "大产品",
                    "第二波大浪潮",
                    "布局良机"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "疫苗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "生物制品-创新疫苗大产品大时代将进入第二波大浪潮，板块迎来布局良机【国盛医药张金洋团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]